Robert W. Baird Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $21.00

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective reduced by equities research analysts at Robert W. Baird from $25.00 to $21.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 281.82% from the stock’s current price.

Several other analysts also recently commented on the stock. HC Wainwright downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research report on Wednesday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

Karyopharm Therapeutics Stock Performance

Shares of KPTI opened at $5.50 on Thursday. The company’s 50 day moving average price is $6.00 and its 200 day moving average price is $5.16. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $16.95. The company has a market capitalization of $47.69 million, a PE ratio of -0.38 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Monday, August 11th. The company reported ($4.32) EPS for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The business had revenue of $37.93 million for the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Several large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its holdings in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. T. Rowe Price Investment Management Inc. acquired a new position in Karyopharm Therapeutics during the 1st quarter valued at $523,000. Two Sigma Investments LP raised its stake in Karyopharm Therapeutics by 60.3% during the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after purchasing an additional 51,856 shares during the last quarter. Silverback Asset Management LLC raised its stake in Karyopharm Therapeutics by 40.0% during the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics during the 2nd quarter valued at $163,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).